Drugs / Vosoritide
Vosoritide
also known as
BMN 111 · Vosoritide Injection · Voxzogo · Modified C-Natriuretic Peptide · ProCNP38 · Vosoritida
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | VOXZOGO | — | 2023-10-20 | fda.gov ↗ |
| Approved | US (FDA) | VOXZOGO | — | 2021-11-19 | fda.gov ↗ |
| Approved | EU (EMA) | Voxzogo | — | 2021-08-26 | europa.eu ↗ |
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05845749 | Sep 2023 → Dec 2028 expected | mucopolysaccharidosis type 4A, mucopolysaccharidosis type 6 | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07126262 | Jul 2025 → Jun 2028 expected | hypochondroplasia | BioMarin Pharmaceutical | Recruiting | No outcome recorded |
| Phase 2 | NCT06668805 | Nov 2024 → Mar 2027 expected | Noonan syndrome | BioMarin Pharmaceutical | Recruiting | No outcome recorded |
| Phase 2 | NCT06382155 | Oct 2024 → Jun 2026 overdue | isolated short stature | BioMarin Pharmaceutical | Recruiting | No outcome recorded |
| Phase 2 | NCT05849389 | Apr 2024 → Sep 2026 expected | Turner syndrome, isolated short stature | Roopa Kanakatti Shankar, MBBS, MS | Recruiting | No outcome recorded |
| Phase 2 | NCT04554940 | Oct 2020 → Dec 2027 expected | achondroplasia | BioMarin Pharmaceutical | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04219007 | Aug 2020 → Aug 2025 overdue | — | Andrew Dauber | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03989947 | Jun 2019 → May 2038 expected | achondroplasia | BioMarin Pharmaceutical | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03583697 | Jun 2018 → Jan 2022 | achondroplasia | BioMarin Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT02724228 | Jan 2016 → Dec 2027 expected | achondroplasia | BioMarin Pharmaceutical | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02055157 | Jan 2014 → Oct 2017 | achondroplasia | BioMarin Pharmaceutical | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07073014 | Jun 2025 → Dec 2040 expected | hypochondroplasia | BioMarin Pharmaceutical | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06455059 | Jun 2024 → Aug 2026 overdue | hypochondroplasia | BioMarin Pharmaceutical | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03424018 | Dec 2017 → Jun 2031 expected | achondroplasia | BioMarin Pharmaceutical | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03197766 | Dec 2016 → Oct 2019 | achondroplasia | BioMarin Pharmaceutical | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01590446 Comparator | Feb → Jun 2012 | achondroplasia | BioMarin Pharmaceutical | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07441876 Comparator | Apr 2026 → Jun 2029 expected | achondroplasia | BioMarin Pharmaceutical | Recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vosoritide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07441876 ↗ |
| Known as | BMN 111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01590446 ↗ |
| Known as | Modified C-Natriuretic Peptide | “Modified C-Natriuretic Peptide, ProCNP38” NCT01590446 ↗ |
| Known as | ProCNP38 | “Modified C-Natriuretic Peptide, ProCNP38” NCT01590446 ↗ |
| Known as | Vosoritida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707276 ↗ |
| Known as | Vosoritide Injection | “Drug: Vosoritide Injection” NCT06668805 ↗1“Drug: Vosoritide Injection” NCT06382155 ↗ |
| Known as | Voxzogo | “Drug: Vosoritide Injection [Voxzogo]” NCT05845749 ↗1“Vosoritide Injection [Voxzogo]” NCT07441876 ↗ |
| Action | Activate | “a selective NPR-B agonist” NCT04219007 ↗ |
| Modality | Peptide | “Modified recombinant human C-type natriuretic peptide” NCT03989947 ↗ |
| Route | Subcutaneous | “SC injection, Part 1 single dose and Part 2 multiple dose.” NCT01590446 ↗ |
| Target | NPR2 | “Atrial natriuretic peptide receptor B binding agent” CHEMBL3707276 ↗ |